|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00133458 |
This study will enroll 120 individuals diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite. This study will determine if two months of albendazole (ABZ) therapy is better than one-month. The study will last 3 years.
Condition | Intervention | Phase |
Subarachnoid Cysticercosis |
Drug: Albendazole |
Phase III |
Drug Information available for: | Albendazole |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Double Blind Comparison of Two Lenghts of Albendazole Therapy for Subarachnoid Cysticercosis |
Estimated Enrollment: | 120 |
Estimated Study Completion Date: | June 2007 |
This is a randomized, double blind comparison of two lengths of albendazole thereapy for subarachnoid cysticercosis. It will enroll 120 individuals, male and female age 18 to 65, and diagnosed with subarachnoid cysticercosis, a disease caused by the invasion of the basal part of your brain by a parasite named Taenia solium. Subarachnoid cysticercosis is usually treated with albendazole for one month to kill the parasite. This study will determine if two months of albendazole (ABZ) therapy is better than one-month. The study will last 3 years.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Brazil | |||||
Facultad de Medicina de Riberao | |||||
Riberao Preto, Brazil, 14020-380 | |||||
Colombia | |||||
Instituto Neurologico de Antioquia | |||||
Medellin, Colombia | |||||
Ecuador | |||||
Neurology Service, Hospital -Clinica Kennedy | |||||
Guayaquil, Ecuador | |||||
Peru | |||||
Universidad Peruana Cayetano Heredia | |||||
Lima, Peru |
Study ID Numbers: | 04-003 |
First Received: | August 19, 2005 |
Last Updated: | June 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00133458 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|